Welcome to our dedicated page for Lantheus Holding SEC filings (Ticker: LNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lantheus Holdings, Inc. (NASDAQ: LNTH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q and 8-K. These documents offer detailed information about Lantheus’ radiopharmaceutical-focused business, financial performance, risk factors, leadership changes and material transactions.
In its Form 8-K filings, Lantheus has reported key corporate events such as quarterly and year-to-date financial results, authorization of a stock repurchase program, acquisitions of Evergreen Theragnostics and Life Molecular Imaging, and the divestiture of its SPECT business. Filings also document leadership transitions, including the planned retirement of the Chief Executive Officer, the appointment of an Executive Chairperson and interim CEO, and changes in other senior roles. These disclosures help investors understand governance and compensation arrangements, including consulting and retirement agreements.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system and summarized on this page) typically contain segment information, discussion of products such as PYLARIFY, DEFINITY and Neuraceq, and descriptions of the company’s precision diagnostics, radiopharmaceutical oncology and strategic partnership activities. They also include extensive risk factor sections that discuss competitive dynamics, manufacturing and supply risks, regulatory considerations for PET imaging agents, and integration risks associated with acquisitions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as changes in outlook, major transactions, or updates on radiopharmaceutical pipeline assets like LNTH-2501 and MK-6240. Users can quickly see high-level insights from lengthy 10-K and 10-Q reports, as well as interpret 8-K items related to leadership changes or capital allocation. The filings page also surfaces insider and executive-related information reported in Forms 3, 4 and 5, allowing investors to monitor equity awards, vesting terms and other compensation-related details disclosed for Lantheus executives and directors.
Lantheus Holdings Chief Commercial Officer Amanda Michelle Morgan reported performance-based stock vesting and related tax share withholding. She acquired 2,782 shares of common stock at no cost from relative total shareholder return PSUs that vested above target. According to the footnote, these PSUs ultimately vested at 162.8% of the target number of shares, so this grant represents the additional shares above the original target previously reported.
On the same date, 3,336 shares of common stock were disposed of at $76.30 per share in a tax-withholding transaction to cover obligations arising from the vesting, rather than an open-market sale. After these transactions, Morgan directly holds 38,540 shares of Lantheus common stock.
Lantheus Holdings CFO and Treasurer Robert J. Marshall Jr. reported two common stock transactions on March 2, 2026. He acquired 8,491 shares at $0.00 per share as a grant or award, increasing his direct holdings to 96,624 shares.
On the same date, he disposed of 10,652 shares of common stock at $76.30 per share in a tax-withholding transaction to cover obligations arising from equity awards, leaving him with 85,972 directly held shares. A footnote explains that the additional shares issued resulted from performance-based PSUs that vested at 162.8% of their target.
Lantheus Holdings Executive Chair and CEO Mary Anne Heino reported a mix of equity award vesting and share withholding for taxes. She acquired 32,105 shares of common stock at $0 per share from the vesting of performance-based restricted stock units tied to relative total shareholder return, after the award paid out at 162.8% of its target.
To cover tax obligations on this vesting, 41,916 shares of common stock were disposed of at $76.30 per share through share withholding, a non-open-market transaction. After these transactions, she directly owns 323,124 common shares.
Lantheus Holdings presents an in-depth annual update highlighting a major strategic shift toward radiopharmaceutical oncology and precision diagnostics. The company relies on key products PYLARIFY, DEFINITY and Neuraceq, supported by AI tools aBSI and aPROMISE and CDMO services acquired with Evergreen.
In 2025–2026, Lantheus executed significant portfolio moves, including selling its SPECT business to SHINE Technologies for consideration of up to $155.0 million, acquiring Life Molecular for $352.9 million in upfront cash plus up to $400.0 million in milestones, and buying Evergreen for $276.4 million upfront with up to $727.5 million in potential milestones.
The report notes a leadership transition with Mary Anne Heino becoming CEO on January 1, 2026, and outlines an extensive pipeline in prostate cancer and Alzheimer’s disease, including MK-6240, NAV-4694, LNTH-2501, LNTH-240x assets and PNT2003. It also summarizes numerous risks: dependence on PYLARIFY and DEFINITY, reimbursement and regulatory uncertainties, integration of acquisitions, patent and ANDA litigation around PNT2003, and competition from large global radiopharmaceutical and imaging players.
Lantheus Holdings reported fourth-quarter 2025 revenue of $406.8 million, up 4.0%, and full-year revenue of $1.54 billion. GAAP diluted EPS was $0.82 for the quarter and $3.41 for 2025, while adjusted diluted EPS reached $1.67 in Q4 and $6.08 for the year.
PYLARIFY sales were $240.2 million in the quarter, down 9.7%, while DEFINITY slipped 1.0% to $85.3 million and Neuraceq contributed $31.0 million. The company repurchased $100 million of stock in Q4 and about $300 million for the year, completed acquisitions of Life Molecular Imaging and Evergreen Theragnostics, and exited its legacy SPECT business. Lantheus is sharpening its focus on innovative PET radiodiagnostics and issued 2026 guidance of $1.4–$1.45 billion in revenue and adjusted diluted EPS of $5.00–$5.25.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 5,707,247 shares of Lantheus Holdings, Inc. common stock, representing 8.6% of the class as of 12/31/2025.
The filing states that various Janus Henderson asset management subsidiaries exercise shared voting and shared dispositive power over these shares on behalf of their clients, referred to as Managed Portfolios. The Managed Portfolios, not Janus Henderson, have the right to receive all dividends and sale proceeds, and no individual Managed Portfolio holds more than five percent of Lantheus’ common stock. Janus Henderson certifies that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Lantheus.
Morgan Stanley filed an amended Schedule 13G showing updated ownership in Lantheus Holdings, Inc. common stock as of December 31, 2025. Morgan Stanley reports beneficial ownership of 1,640,837 shares, representing 2.5% of the class, with all voting and dispositive power shared among its reporting units.
Morgan Stanley Capital Services LLC separately reports beneficial ownership of 936,899 shares, or 1.4% of the class, with shared voting and dispositive power. Both reporting persons state they have ceased to be beneficial owners of more than five percent of Lantheus’s common stock and certify that the holdings are in the ordinary course of business and not for influencing control.
Farallon-affiliated funds and managers report a significant passive stake in Lantheus Holdings, Inc. As of the event date of 12/31/2025, the Farallon reporting group discloses beneficial ownership of 5,427,479 shares of Lantheus common stock, representing 8.2% of the outstanding Shares.
The Amendment notes internal leadership changes at Farallon entities. Effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased to be deemed beneficial owners. Effective January 1, 2026, Avner A. Husen became a member and manager of several Farallon general partners and may be deemed a beneficial owner. The group certifies the holdings are not for changing or influencing control of Lantheus.
A shareholder has filed a notice of proposed sale of 6,713 shares of common stock, with an aggregate market value of 449,570.29. The shares are to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/02/2026. The issuer has 66,311,779 common shares outstanding.
The shares to be sold were acquired through restricted stock vesting and employee stock purchase plan transactions between 03/03/2022 and 09/12/2025. The filing also lists prior sales over the past three months by Paul M. Blanchfield, including multiple common stock sales with stated gross proceeds.
Lantheus Holdings’ Chief Commercial Officer reported small changes in personal ownership of the company’s common stock related to transactions on December 15, 2024 and December 15, 2025. The transactions, each coded "F," involved the disposition of 356 shares at $93.48 and 368 shares at $66.57.
After the December 2024 transaction, the officer beneficially owned 25,055 shares. After the December 2025 transaction, beneficial ownership increased to 39,094 shares, which includes 143 shares acquired under the LNTH employee stock purchase plan on March 13, 2025, and 95 shares acquired under the same plan on September 12, 2025.